Yuval Cohen, Ph.D.Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V.
Craig Millian, MBAChief Operating Officer
Craig Millian serves as Corbus’ Chief Operating Officer. Mr. Millian has successfully led commercial organizations at several biopharmaceutical companies and helped build leading brands at all stages of product development and commercialization. He previously served as Chief Commercial Officer at Corbus. Before joining Corbus in February 2019, Mr. Millian held various leadership positions at EMD Serono, including Senior Vice President, Head of U.S. Fertility and Endocrinology, and Senior Vice President, Head of U.S. Neurology and Immunology. In these roles, he was responsible for leading the strategic direction and driving operating results for these franchises in the U.S. He oversaw key areas of the business, including sales, marketing and patient support services. Previously, Mr. Millian served as Vice President, Commercial at Vertex, where he helped design and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product pipeline. Prior to Vertex, he held commercial leadership roles at Pfizer Inc. and Sanofi. Mr. Millian holds an MBA from New York University and a degree in Finance from the University of Pennsylvania.
Sean Moran, CPA, MBAChief Financial Officer
Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran has successfully managed operations from start up through development to commercialization and profitability. He has completed three IPOs and has raised more than $500 million of capital. Before joining Corbus, Mr. Moran served as Chief Financial Officer for InVivo Therapeutics, Celsion Corporation, Echo Therapeutics, and Anika Therapeutics. Mr. Moran earned his M.B.A. and a B.S. in Accounting from Babson College in Wellesley, MA.
Ross LobellVice President, Regulatory Affairs
Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations to support the drug development process. Prior to his appointment at Corbus, he held various leadership positions across several global pharmaceutical companies, including Schering-Plough, Pfizer, Amgen and AstraZeneca/MedImmune. During his tenure at MedImmune, Mr. Lobell oversaw all regulatory affairs support for the Respiratory, Inflammation and Anti-Inflammatory biologics programs. Over the course of his career, Mr. Lobell led development, registration and post-registration activities for small-molecule and biologic medicines in multiple therapeutic areas, including oncology, rheumatology, respiratory, women’s health and cardiology/lipid metabolism. Additionally, he oversaw the development, submission and review management process for New Drug Applications, Biologics License Applications, and supplemental efficacy applications to expand labeling. Mr. Lobell received his Bachelor of Science in Biology from Lebanon Valley College.
Dylan WenkeHead, Business Development
Dylan Wenke joined Corbus in May 2017 to create the business development function. He is responsible for corporate development, partnerships, and collaborations. Throughout his time at Corbus he has driven several of the company’s key transactions, including the licensing agreement with Jenrin in 2018, the licensing agreement with Kaken in 2019, and the structured financing agreement with K2 HealthVentures in 2020. Before joining Corbus, Dylan served in business development roles at a venture backed start-up. He earned his B.Sc. in Chemistry from the University of North Florida.
Christina BertschHead of Human Resources
Christina Bertsch joined Corbus in April 2020. She is an accomplished senior human resource executive providing strategic HR consulting services to both large and small businesses across a variety of industries. Her expertise spans the full employee lifecycle including talent acquisition, workforce development, performance management, succession planning, total rewards as well as employee engagement and retention. In addition to her expertise, Christina also has significant experience in HR strategic planning, mergers & acquisitions, change management, executive coaching & development and building scalable HR infrastructures for growing companies.
Ms. Bertsch has worked with a number of organizations within the life sciences space including Stoke Therapeutics, Jounce Therapeutics, Magenta Therapeutics, Ironwood, Bruker, Merus, and Sarepta Therapeutics. Previous to starting her consulting business she was Senior Vice President of Human Resources at Santander Holdings US, Vice President of Human Resources at Beacon Partners and Director of Talent Management & Development at EMD Serono.
She holds a Bachelor’s Degree from Manhattanville College, and a Master’s Degree in Industrial / Organizational Psychology from Hofstra University.